Relypsa, Sanofi in starting gate for patiromer launch, with FDA decision imminent

Relypsa ($RLYP) and Sanofi ($SNY) are raring to go for a prospective launch of patiromer, a treatment for hyperkalemia. And they need to get going, considering a competitor med might hit the market in mid-2016. All they need is an FDA approval, and that yea-or-nay decision is expected today. More from FiercePharmaMarketing

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.